Campbell & Co Investment Adviser’s Tvardi Therapeutics TVRD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-440	Closed	-$77.8K	–	1163
2023 Q1	$77.8K	Hold	440	–	–	0.01%	778
2022 Q4	$170K	Buy	+440	New	+$167K	0.04%	712
2021 Q4	–	Sell	-1,183	Closed	-$658K	–	857
2021 Q3	$658K	Buy	+1,183	New	+$593K	0.21%	144
2020 Q4	–	Sell	-379	Closed	-$173K	–	592
2020 Q3	$173K	Buy	+379	New	+$220K	0.13%	322

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's TVRD Position: Q2 2023 in Review

Campbell & Co Investment Adviser sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 440 shares — an estimated $77.8K sold.

Campbell & Co Investment Adviser first reported a position in TVRD in Q3 2020 and held it in 4 quarters. The position peaked at $658K in Q3 2021. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

Campbell & Co Investment Adviser reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
Campbell & Co Investment Adviser sold 440 Tvardi Therapeutics shares in Q2 2023, an estimated $77.8K.
Campbell & Co Investment Adviser first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 4 quarters.
Campbell & Co Investment Adviser's Tvardi Therapeutics position peaked at $658K in Q3 2021.
137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.